Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 4/2016

01-04-2016 | Original Article

Multimodal imaging based on MRI and PET reveals [18F]FLT PET as a specific and early indicator of treatment efficacy in a preclinical model of recurrent glioblastoma

Authors: Aurélien Corroyer-Dulmont, Elodie A. Pérès, Aurélie N. Gérault, Ariel Savina, Fanny Bouquet, Didier Divoux, Jérôme Toutain, Méziane Ibazizène, Eric T. MacKenzie, Louisa Barré, Myriam Bernaudin, Edwige Petit, Samuel Valable

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 4/2016

Login to get access

Abstract

Purpose

The primary objective of this study was to compare the ability of PET and MRI biomarkers to predict treatment efficacy in a preclinical model of recurrent glioblastoma multiforme.

Methods

MRI (anatomical, diffusion, vasculature and oxygenation) and PET ([18F]FDG and [18F]FLT) parameters were obtained 3 days after the end of treatment and compared with late tumour growth and survival.

Results

Early after tumour recurrence, no effect of treatment with temozolomide combined with bevacizumab was observed on tumour volume as assessed by T2-W MRI. At later times, the treatment decreased tumour volume and increased survival. Interestingly, at the earlier time, temozolomide + bevacizumab decreased [18F]FLT uptake, cerebral blood volume and oedema. [18F]FLT uptake, oedema and cerebral blood volume were correlated with overall survival but [18F]FLT uptake had the highest specificity and sensitivity for the early prediction of treatment efficacy.

Conclusion

The present investigation in a preclinical model of glioblastoma recurrence underscores the importance of multimodal imaging in the assessment of oedema, tumour vascular status and cell proliferation. Finally, [18F]FLT holds the greatest promise for the early assessment of treatment efficacy. These findings may translate clinically in that individualized treatment for recurrent glioma could be prescribed for patients selected after PET/MRI examinations.
Appendix
Available only for authorised users
Literature
1.
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.CrossRefPubMed
2.
Desjardins A, Friedman HS. Neuro-oncology: glioblastoma – community adjusts to new standard of care. Nat Rev Neurol. 2012;8:244–6.CrossRefPubMed
3.
Eftimov N, Ivanov ID, Petkov AP, Nakov E. Management of recurrent high-grade gliomas. Cancer Ther. 2007;5:243–52.
4.
Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 2014;15:943–53.CrossRefPubMed
5.
Miletic H, Niclou SP, Johansson M, Bjerkvig R. Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms. Expert Opin Ther Targets. 2009;13:455–68.CrossRefPubMed
6.
7.
Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733–40.CrossRefPubMed
8.
Van Linde ME, Verhoeff JJ, Richel DJ, van Furth WR, Reijneveld JC, Verheul HM, et al. Bevacizumab in combination with radiotherapy and temozolomide for patients with newly diagnosed glioblastoma multiforme. Oncologist. 2015;20:107–8.
9.
Corroyer-Dulmont A, Pérès EA, Petit E, Guillamo J-S, Varoqueaux N, Roussel S, et al. Detection of glioblastoma response to temozolomide combined with bevacizumab based on μMRI and μPET imaging reveals [18F]-fluoro-L-thymidine as an early and robust predictive marker for treatment efficacy. Neuro Oncol. 2013;15:41–56.PubMedCentralCrossRefPubMed
10.
Pope WB, Lai A, Mehta R, Kim HJ, Qiao J, Young JR, et al. Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma. AJNR Am J Neuroradiol. 2011;32:882–9.CrossRefPubMed
11.
Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Geist C, et al. 3′-Deoxy-3′-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. J Nucl Med. 2012;53:29–36.PubMedCentralCrossRefPubMed
12.
Viel T, Schelhaas S, Wagner S, Wachsmuth L, Schwegmann K, Kuhlmann M, et al. Early assessment of the efficacy of temozolomide chemotherapy in experimental glioblastoma using [18F]FLT-PET imaging. PLoS One. 2013;8, e67911.PubMedCentralCrossRefPubMed
13.
Lemasson B, Christen T, Serduc R, Maisin C, Bouchet A, Le Duc G, et al. Evaluation of the relationship between MR estimates of blood oxygen saturation and hypoxia: effect of an antiangiogenic treatment on a gliosarcoma model. Radiology. 2012;265:743–52.CrossRefPubMed
14.
Jordan BF, Magat J, Colliez F, Ozel E, Fruytier AC, Marchand V, et al. Mapping of oxygen by imaging lipids relaxation enhancement: a potential sensitive endogenous MRI contrast to map variations in tissue oxygenation. Magn Reson Med. 2013;70:732–44.CrossRefPubMed
15.
Emblem KE, Mouridsen K, Bjornerud A, Farrar CT, Jennings D, Borra RJH, et al. Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy. Nat Med. 2013;19:1178–83.PubMedCentralCrossRefPubMed
16.
Ullrich R, Backes H, Li H, Kracht L, Miletic H, Kesper K, et al. Glioma proliferation as assessed by 3′-fluoro-3′-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma. Clin Cancer Res. 2008;14:2049–55.CrossRefPubMed
17.
Hutterer M, Nowosielski M, Putzer D, Waitz D, Tinkhauser G, Kostron H, et al. O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma. J Nucl Med. 2011;52:856–64.CrossRefPubMed
18.
Derlon JM, Chapon F, Noël MH, Khouri S, Benali K, Petit-Taboué MC, et al. Non-invasive grading of oligodendrogliomas: correlation between in vivo metabolic pattern and histopathology. Eur J Nucl Med. 2000;27:778–87.CrossRefPubMed
19.
Chen W, Delaloye S, Silverman DHS, Geist C, Czernin J, Sayre J, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol. 2007;25:4714–21.CrossRefPubMed
20.
Corroyer-Dulmont A, Pérès EA, Petit E, Durand L, Marteau L, Toutain J, et al. Noninvasive assessment of hypoxia with 3-[18F]-fluoro-1-(2-nitro-1-imidazolyl)-2-propanol ([18F]-FMISO): a PET study in two experimental models of human glioma. Biol Chem. 2013;394:529–39.CrossRefPubMed
21.
Valable S, Eddi D, Constans J-M, Guillamo J-S, Bernaudin M, Roussel S, et al. MRI assessment of hemodynamic effects of angiopoietin-2 overexpression in a brain tumor model. Neuro Oncol. 2009;11:488–502.PubMedCentralCrossRefPubMed
22.
Varallyay C, Muldoon L, Gahramanov S. Dynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model. J Cereb Blood Flow Metab. 2009;29:853–60.PubMedCentralCrossRefPubMed
23.
Valable S, Petit E, Roussel S, Marteau L, Toutain J, Divoux D, et al. Complementary information from magnetic resonance imaging and (18)F-fluoromisonidazole positron emission tomography in the assessment of the response to an antiangiogenic treatment in a rat brain tumor model. Nucl Med Biol. 2011;38:781–93.PubMed
24.
Lemasson B, Valable S, Farion R, Krainik A, Rémy C, Barbier EL. In vivo imaging of vessel diameter, size, and density: a comparative study between MRI and histology. Magn Reson Med. 2013;69:1–3.CrossRef
25.
Hawkins-Daarud A, Rockne RC, Anderson AR, Swanson KR. Modeling tumor-associated edema in gliomas during anti-angiogenic therapy and its impact on imageable tumor. Front Oncol. 2013;3:66.PubMedCentralCrossRefPubMed
26.
Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Lalezari S, Zaw T, et al. Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab. J Neurooncol. 2012;106:111–9.CrossRefPubMed
27.
Roth P, Regli L, Tonder M, Weller M. Tumor-associated edema in brain cancer patients: pathogenesis and management. Expert Rev Anticancer Ther. 2013;13:1319–25.CrossRefPubMed
28.
Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 2004;4:437–47.CrossRefPubMed
29.
30.
McGee MC, Hamner JB, Williams RF, Rosati SF, Sims TL, Ng CY, et al. Improved intratumoral oxygenation through vascular normalization increases glioma sensitivity to ionizing radiation. Int J Radiat Oncol Biol Phys. 2010;76:1537–45.PubMedCentralCrossRefPubMed
31.
Pérès EA, Gérault AN, Valable S, Roussel S. Silencing erythropoietin receptor on glioma cells reinforces efficacy of temozolomide and X-rays through senescence and mitotic catastrophe. Oncotarget. 2015;6:2101–19.PubMedCentralCrossRefPubMed
32.
Zhao F, Cui Y, Li M, Fu Z, Chen Z, Kong L, et al. Prognostic value of 3′-Deoxy-3′-18F-Fluorothymidine ([18F] FLT PET) in patients with recurrent malignant gliomas. Nucl Med Biol. 2014;41:710–5.
33.
Oborski MJ, Laymon CM, Lieberman FS, Drappatz J, Hamilton RL, Mountz JM. First use of 18F-labeled ML-10 PET to assess apoptosis change in a newly diagnosed glioblastoma multiforme patient before and early after therapy. Brain Behav. 2014;4:312–5.PubMedCentralCrossRefPubMed
34.
Wardak M, Schiepers C, Cloughesy TF, Dahlbom M, Phelps ME, Huang SC. 18F-FLT and 18F-FDOPA PET kinetics in recurrent brain tumors. Eur J Nucl Med Mol Imaging. 2014;41:1199–209.PubMedCentralCrossRefPubMed
35.
Jeong SY, Lim SM. Comparison of 3′-deoxy-3′-[(18)F]fluorothymidine PET and O-(2-[(18)F]fluoroethyl)-L-tyrosine PET in patients with newly diagnosed glioma. Nucl Med Biol. 2012;39:977–81.CrossRefPubMed
36.
Seung JC, Jae SK, Jeong HK, Seung JO, Jeong GL, Chang JK, et al. [18F]3′-deoxy-3′-fluorothymidine PET for the diagnosis and grading of brain tumors. Eur J Nucl Med Mol Imaging. 2005;32:653–9.CrossRef
37.
Yamamoto Y, Wong TZ, Turkington TG, Hawk TC, Reardon DA, Coleman RE. 3′-Deoxy-3′-[F-18]fluorothymidine positron emission tomography in patients with recurrent glioblastoma multiforme: comparison with Gd-DTPA enhanced magnetic resonance imaging. Mol Imaging Biol. 2006;8:340–7.CrossRefPubMed
38.
Radaelli E, Ceruti R, Patton V, Russo M, Degrassi A, Croci V, et al. Immunohistopathological and neuroimaging characterization of murine orthotopic xenograft models of glioblastoma multiforme recapitulating the most salient features of human disease. Histol Histopathol. 2009;24:879–91.PubMed
39.
Godoy PR, Mello SS, Magalhães DA, Donaires FS, Nicolucci P, Donadi EA, et al. Ionizing radiation-induced gene expression changes in TP53 proficient and deficient glioblastoma cell lines. Mutat Res. 2013;756:46–55.CrossRefPubMed
Metadata
Title
Multimodal imaging based on MRI and PET reveals [18F]FLT PET as a specific and early indicator of treatment efficacy in a preclinical model of recurrent glioblastoma
Authors
Aurélien Corroyer-Dulmont
Elodie A. Pérès
Aurélie N. Gérault
Ariel Savina
Fanny Bouquet
Didier Divoux
Jérôme Toutain
Méziane Ibazizène
Eric T. MacKenzie
Louisa Barré
Myriam Bernaudin
Edwige Petit
Samuel Valable
Publication date
01-04-2016
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 4/2016
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-015-3225-0

Other articles of this Issue 4/2016

European Journal of Nuclear Medicine and Molecular Imaging 4/2016 Go to the issue

Editorial Commentary

Evaluation of neck node response after radiotherapy: minimizing equivocal results

Original Article

Predictors of ventricular remodelling in patients with reperfused acute myocardial infarction and left ventricular dysfunction candidates for bone marrow cell therapy: insights from the BONAMI trial

Society Communications

EANM Springer Prizes awarded at EANM’15 Hamburg

Original Article

Quantitative and qualitative analysis of [18F]FDG and [18F]FAZA positron emission tomography of head and neck cancers and associations with HPV status and treatment outcome

Original Article

Nuclear cardiology practice and associated radiation doses in Europe: results of the IAEA Nuclear Cardiology Protocols Study (INCAPS) for the 27 European countries

UEMS/EBNM

Nuclear medicine training and practice in the UK